Abstracts tagged "lupus nephritis and pediatric rheumatology"

Abstract Number: 2019 • 2018 ACR/ARHP Annual Meeting
Investigating Urine S100A4 and Podocyte Proteins As Biomarkers of Lupus Nephritis Activity
Jessica Turnier¹, Jianghong Deng², Pinar Ozge Avar Aydin³, David Witte⁴, Prasad Devarajan⁵, Matthew Fenchel⁶, Michael Bennett⁷ and Hermine I. Brunner⁸, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Beijing Children’s Hospital and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁶Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: We lack accurate clinical tools to identify the degree of active renal inflammation in childhood-onset SLE (cSLE). In this study, we investigated urine S100A4…
Abstract Number: 93 • 2017 Pediatric Rheumatology Symposium
Corticosteroid Regimen Use in the Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Jennifer C. Cooper¹, B. Anne Eberhard², Marilynn Punaro³, Stacy P. Ardoin⁴, Hermine Brunner⁵, Joyce Hsu⁶, Linda Wagner-Weiner⁷, Marisa Klein-Gitelman⁸, Kelly A. Rouster-Stevens⁹, Laura E. Schanberg¹⁰, Emily von Scheven¹¹ and the CARRA Investigators, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Cohen Children's Medical Center of New York, New Hyde Park, NY, ³Texas Scottish Rite Hospital for Children, Dallas, TX, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷University of Chicago Hospital, Chicago, IL, ⁸Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ¹⁰Pediatrics, Duke Medical Center, Durham, NC, ¹¹Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA
Background/Purpose: Comparative data in the pediatric lupus nephritis (LN) population are lacking. To reduce treatment variability and facilitate comparative effectiveness studies, the Childhood Arthritis and…
Abstract Number: 1380 • 2016 ACR/ARHP Annual Meeting
Multicenter Prospective Study on the Role of Urinary HER2 As a Lupus Nephritis Biomarker
Patrícia Costa Reis¹, Kelly Maurer², Emily von Scheven³, Kathleen O'Neil⁴, Jon M. Burnham⁵, Laura E. Schanberg⁶, Michelle Petri⁷ and Kathleen E. Sullivan⁸, ¹Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, ⁴Pediatrics, Indiana University, Indianapolis, IN, ⁵Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ⁶Pediatrics, Duke Medical Center, Durham, NC, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: HER2 (Human Epidermal Growth Factor Receptor 2) is dramatically overexpressed in the glomeruli and in the tubular compartment of patients with lupus nephritis, but…
Abstract Number: 406 • 2015 ACR/ARHP Annual Meeting
Long Term Follow up of Inner City Pediatric Patients with Lupus Nephritis
Janice Desir¹, Beatrice Goilav², Ellen Silver³ and Irene Blanco⁴, ¹Pediatric Nephrology, Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, ²Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ³Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁴Medicine, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: In children with SLE, 80% have renal involvement, which is a major prognostic factor for both morbidity and mortality. Few studies have focused on…
Abstract Number: 2860 • 2013 ACR/ARHP Annual Meeting
Mir-26a, Mir-30b and HER2: New Players On Lupus Nephritis Pathogenesis
Patrícia Costa-Reis¹, Pierre Russo² and Kathleen E. Sullivan³, ¹Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: microRNAS (miRNAs) are noncoding RNAs responsible for post-transcriptional gene silencing. These key regulatory molecules control the expression of multiple genes, so its dysregulation can…
Abstract Number: 305 • 2012 ACR/ARHP Annual Meeting
Clinicopathologic Correlates for Activity and Damage of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus
Ravi Nunna¹, Rina Mina¹, Michael Bennett², Shannen Nelson³, Jessica Hummel⁴, Prasad Devarajan², David Witte³ and Hermine Brunner⁵, ¹Rheumatology, Cincinnati Children's Hospital Medical Center/University of Cincinnati, Cincinnati, OH, ²Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: High AI activity (AI), tubulointerstitial (TI), and chronicity index (CI) scores from renal biopsy may predict poor renal outcomes in lupus nephritis (LN)…
Abstract Number: 308 • 2012 ACR/ARHP Annual Meeting
Next-Generation Sequencing of Urinary Microrna in Human Lupus Nephritis
Beatrice Goilav¹, Iddo Z. Ben-Dov², Irene Blanco³, Olivier Loudig⁴, Dawn M. Wahezi⁵ and Chaim Putterman⁶, ¹Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ²Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Epidemiology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatric Rheumatology, Children's Hospital Montefiore, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a common manifestation of SLE associated with significant morbidity and mortality. microRNAs (miRs) are small non-coding RNAs that regulate translation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].